The AR-antagonists were also evaluated for their in vivo efficacy in castrated VCaP tumor-bearing-CB17/lcr-Prkdc SCID mice treated with 25 mg/kg of Compound 30 and 100 mg/kg of Compound 26 daily by oral gavage. The gene discussed is AR; the disease is neoplasm.